ProStrakan reports revenue growth in first half

ProStrakan has experienced a strong first half of 2010, generating revenues of 45.4 million pounds for the six-month period.

The pharmaceutical company's total year-on-year revenue growth for the half-year stood at 23 per cent, while significant gains were also seen in terms of gross profits and earnings.

This expansion was attributed primarily to the firm's strong growth in Europe, where revenues increased by 26 per cent thanks to rising sales of products such as Abstral and Adcal-D3.

Dr Wilson Totten, chief executive of ProStrakan, also highlighted the growing strength of its US operations and international partners scheme as further reasons for confidence.

He said: "Our clear strategic focus is on growing our broad portfolio of patient-friendly products and to promote these products through our own sales forces … while seeking out high quality partners for other countries."

Earlier this year, ProStrakan was presented with the Award for Innovation at the Scottish PLC Awards, honouring the new products it launched during 2009.